07:00 , Oct 20, 2014 |  BC Week In Review  |  Company News

Asterand Bioscience, ReproCell deal

ReproCell acquired the induced pluripotent stem cell (iPSC) reagents and services business of Stemgent Inc. , now known as Asterand Biosciences Inc., for about $8.5 million in cash. Asterand will now focus on its human...
07:00 , Sep 23, 2013 |  BC Week In Review  |  Company News

DiscoveRx sales and marketing update

DiscoveRx's BioSeek division launched the human primary cell-based BioMAP panel to assess the phenotypic effect of drug candidates on tumor microenvironment biology. DiscoveRx said the panel enables researchers to better predict in vivo drug activities...
08:00 , Nov 12, 2012 |  BC Week In Review  |  Company News

BioSeek, DiscoveRx deal

DiscoveRx acquired fellow drug discovery services company BioSeek. The deal gives DiscoveRx access to BioSeek's BioMAP Systems predictive cell-based disease model technology. The companies declined to disclose details. BioSeek plc , South San Francisco, Calif....
07:00 , Oct 15, 2012 |  BC Week In Review  |  Company News

BioSeek, EPA deal

BioSeek received a contract from the U.S. Environmental Protection Agency under the EPA ToxCast screening program to use BioSeek's BioMAP Systems to help predict biological activity and potential toxicity. The deal will cover up to...
07:00 , Aug 6, 2012 |  BC Week In Review  |  Company News

BioSeek, Stemgent deal

BioSeek, formerly Asterand plc , completed the sale of its non-BioSeek Tissue Based Solutions business to Stemgent for $9 million in cash (see BioCentury, July 23). BioSeek plc (LSE:ATD), Royston, U.K.   Stemgent Inc. ,...
07:00 , Jul 23, 2012 |  BC Week In Review  |  Company News

Asterand, Stemgent deal

In June, Stemgent said it will acquire Asterand's non-BioSeek Tissue Based Solutions business for $9 million in cash. At the time, the company also proposed to delist its shares. In a July 13 shareholder circular,...
07:00 , May 7, 2012 |  BC Week In Review  |  Company News

Asterand deal

The tools and tissue-based research services company said that it received notice that a potential bidder will no longer seek acquisition of Asterand's BioSeek Inc. business. Last month, Asterand said that it signed letters of...
07:00 , Apr 30, 2012 |  BioCentury  |  Emerging Company Profile

Ariel: Antagonizing pain

Although standard of care treatments raise safety concerns, along with high rates of non-responders, the pipeline for acute pain continues to be short on novel targets. Ariel Pharmaceuticals Inc. is developing an in-licensed PTGER4 antagonist...
07:00 , Apr 2, 2012 |  BC Week In Review  |  Company News

Asterand, Merck KGaA deal

Asterand's BioSeek LLC subsidiary and Merck's Merck Serono division extended by three years to March 2015 a 2009 deal to use BioSeek's BioMAP systems to evaluate small molecule compounds and proteins from Merck Serono to...
08:00 , Jan 9, 2012 |  BC Week In Review  |  Company News

Asterand functional genomics, admet, supply/service news

The board of the tools and tissue-based research services company extended to Jan. 17 the deadline for submissions of potential offers to acquire all or part of the business. The extension, which will allow potential...